Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 1 day ago
- 1 min read
10/08/2026
MoonLake announced Phase 3 results of Sonelokimab in Psoriatic Arthritis (Ref)
MoonLake Immunotherapeutics announced positive topline results from the Phase 3, IZAR-1/ NCT06641076 trial evaluating sonelokimab in biologic-naïve adults with active psoriatic arthritis (PsA).
The trial met all the clinical endpoint at week 16 for 60 mg sonelokimab with induction.
The primary endpoint of ACR50 was met with a response of 42.1% for sonelokimab 60 mg with induction, and significant responses were reported across key secondary endpoints, including ACR20 (66.5%), MDA (41.2%) and PASI90 (61%), supporting the broad multidomain efficacy profile of sonelokimab in psoriatic arthritis.
Meaningful and statistically significant improvements were reported across patient-reported outcomes and physical function measures, including HAQ-DI and SF-36 PCS.
The blinded safety analysis suggested a profile consistent with previous studies and no new safety signals were identified.
The IZAR-1 trial remains blinded and was set to continue to Week 52 with MoonLake expecting the full readout in H1 2027
The IZAR-2/ NCT06641089 trial (a trial in TNF-refractory patients) was expected to complete enrollment in Q3 2026.
